The Journal of urology · 2025
Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Donat Sherri M, Tin Amy L, Vickers Andrew J, Herr Harry
Аннотация
PURPOSE: Bladder preservation is a desired goal for most patients with muscle-invasive bladder cancer, although select few are ideal candidates based on established criteria. Heterogenous cohorts with short follow-up hinder assessment of true risks/benefits for ideal candidates. We describe long-term outcomes in patients with muscle-invasive bladder cancer, meeting established ideal criteria for bladder preservation, treated initially with systemic therapy and transurethral resection (TUR).
MATERIALS AND METHODS: We conducted an institutional retrospective review of 101 prospectively monitored patients meeting "ideal" criteria for bladder preservation achieving a clinical complete response to cisplatin-based chemotherapy and TUR from 1994 to 2015, with > 10 years of follow-up. Primary end points were bladder-intact survival, local recurrence-free survival, and cancer-specific survival.
RESULTS: Fifteen-year risk of death from bladder cancer was 11% (95% CI: 5.8%, 18%), with the competing risk of death from other causes 44% (95% CI: 33%, 54%) and cystectomy risk of 11% (95% CI: 5.9%, 18%). Bladder preservation outcomes were near 40:40:10:10 for death from another cause, alive with an intact bladder, cystectomy, and death from bladder cancer. Of 41 patients alive with their bladder intact, median (IQR) follow-up time was 14 (11, 20) years. One-third relapsed locally, with the probability persisting beyond 10 years, necessitating lifetime surveillance. Our findings may not be generalizable to other settings or to patients not meeting "ideal" criteria.
CONCLUSIONS: Bladder preservation with neoadjuvant chemotherapy with TUR is a viable option for select patients meeting established selection criteria. Patients and physicians must consider the probabilities of long-term bladder preservation vs excess mortality when electing bladder-sparing.
MATERIALS AND METHODS: We conducted an institutional retrospective review of 101 prospectively monitored patients meeting "ideal" criteria for bladder preservation achieving a clinical complete response to cisplatin-based chemotherapy and TUR from 1994 to 2015, with > 10 years of follow-up. Primary end points were bladder-intact survival, local recurrence-free survival, and cancer-specific survival.
RESULTS: Fifteen-year risk of death from bladder cancer was 11% (95% CI: 5.8%, 18%), with the competing risk of death from other causes 44% (95% CI: 33%, 54%) and cystectomy risk of 11% (95% CI: 5.9%, 18%). Bladder preservation outcomes were near 40:40:10:10 for death from another cause, alive with an intact bladder, cystectomy, and death from bladder cancer. Of 41 patients alive with their bladder intact, median (IQR) follow-up time was 14 (11, 20) years. One-third relapsed locally, with the probability persisting beyond 10 years, necessitating lifetime surveillance. Our findings may not be generalizable to other settings or to patients not meeting "ideal" criteria.
CONCLUSIONS: Bladder preservation with neoadjuvant chemotherapy with TUR is a viable option for select patients meeting established selection criteria. Patients and physicians must consider the probabilities of long-term bladder preservation vs excess mortality when electing bladder-sparing.